Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 15/20 | 0.57 |
| ▸ | HDAC2 | Q92769 | 4/20 | 0.42 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.41 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.41 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.41 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.41 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.41 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.41 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3573471 | 0.89 | HDAC1 (0.56) | HDAC1HDAC2ADORA3 | |
| SCHEMBL3578064 | 0.83 | HDAC1 (0.42) | HDAC1HDAC2ADORA3 | |
| SCHEMBL2440113 | 0.81 | TMIGD3 (0.49) | HDAC1HDAC2HDAC3HDAC4HDAC7 | |
| SCHEMBL3575136 | 0.81 | HDAC1 (0.67) | HDAC1HDAC2HDAC3HDAC4HDAC7 | |
| SCHEMBL3572237 | 0.77 | HDAC1 (0.73) | HDAC1HDAC2HDAC3HDAC4HDAC7 | |
| SCHEMBL3565538 | 0.76 | HDAC1 (0.74) | HDAC1HDAC2HDAC3HDAC4HDAC7 | |
| SCHEMBL3578725 | 0.75 | HDAC2 (0.61) | HDAC1HDAC2HDAC3HDAC4HDAC7 | |
| SCHEMBL1888904 | 0.74 | HDAC1 (1.00) | HDAC1HDAC2HDAC3HDAC4HDAC7 | |
| SCHEMBL4453120 | 0.73 | HDAC1 (0.52) | HDAC1HDAC2HDAC3HDAC4HDAC7 | |
| SCHEMBL3576307 | 0.73 | HDAC2 (0.64) | HDAC1HDAC2HDAC3HDAC4HDAC7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7834034-B2 | Benzothiophene derivatives | MERCK SHARP & DOHME CORP. (US) | 2010-11-16 | — | — | US | disclosed |
| US-7834034-B2 | Benzothiophene derivatives | MERCK SHARP & DOHME CORP. (US) | 2010-11-16 | — | — | US | disclosed |
| US-7834034-B2 | Benzothiophene derivatives | MERCK SHARP & DOHME CORP. (US) | 2010-11-16 | — | — | US | disclosed |
| EP-1874295-A4 | BENZOTHIOPHENE DERIVATIVES | MERCK & CO INC (US) | 2009-08-12 | — | — | EP | disclosed |
| US-20090082308-A1 | Benzothiophene derivatives | MERCK SHARP & DOHME LLC | 2009-03-26 | — | — | US | disclosed |
| US-20090082308-A1 | Benzothiophene derivatives | MERCK SHARP & DOHME LLC | 2009-03-26 | — | — | US | disclosed |
| US-20090082308-A1 | Benzothiophene derivatives | MERCK SHARP & DOHME LLC | 2009-03-26 | — | — | US | disclosed |
| US-20090012075-A1 | Fluorinated Arylamide Derivatives | MERCK SHARP & DOHME CORP. | 2009-01-08 | — | — | US | disclosed |
| US-20090012075-A1 | Fluorinated Arylamide Derivatives | MERCK SHARP & DOHME CORP. | 2009-01-08 | — | — | US | disclosed |
| US-20090012075-A1 | Fluorinated Arylamide Derivatives | MERCK SHARP & DOHME CORP. | 2009-01-08 | — | — | US | disclosed |
| EP-1976511-A2 | FLUORINATED ARYLAMIDE DERIVATIVES | Merck & Co., Inc. (US) | 2008-10-08 | — | — | EP | disclosed |
| EP-1874295-A1 | BENZOTHIOPHENE DERIVATIVES | Merck & Co., Inc. (US) | 2008-01-09 | — | — | EP | disclosed |
| WO-2007087129-A2 | FLUORINATED ARYLAMIDE DERIVATIVES | MERCK & CO., INC. (US) | 2007-08-02 | — | — | WO | disclosed |
| WO-2007087129-A2 | FLUORINATED ARYLAMIDE DERIVATIVES | MERCK & CO., INC. (US) | 2007-08-02 | — | — | WO | disclosed |
| WO-2006115845-A1 | BENZOTHIOPHENE DERIVATIVES | MERCK & CO., INC. (US) | 2006-11-02 | — | — | WO | disclosed |
| WO-2006115845-A1 | BENZOTHIOPHENE DERIVATIVES | MERCK & CO., INC. (US) | 2006-11-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090012075-A1 | Fluorinated Arylamide Derivatives | HDAC5, AADAC, HDAC6 | HDAC1 4/4885HDAC2 7/4885HDAC3 6/4885 |
| US-20090082308-A1 | Benzothiophene derivatives | BRDT, HDAC5, BRPF3 | HDAC1 4/4885HDAC2 8/4885HDAC3 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.